CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Ide-cel Produces PFS Benefit Vs Standard Regimens in Relapsed/Refractory Multiple Myeloma

August 10th 2022

Idecabtagene vicleucel elicited a statistically significant improvement in progression-free survival vs standard combination regimens in patients with relapsed/refractory multiple myeloma who had received 2 to 4 lines of prior therapy.

CAR T-cell Therapy CT103A Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 3rd 2022

The fully human BCMA-directed CAR T-cell therapy, CT103A, demonstrated deepening efficacy with an acceptable toxicity profile in patients with relapsed or refractory multiple myeloma, according to updated data from the phase 1/2 FUMANBA-1 trial.

FDA Lifts Clinical Hold on KEYNOTE-B79 Trial Evaluating CAR T-cell Therapy CYAD-101 in Metastatic CRC

August 1st 2022

The FDA has lifted a clinical hold on the phase 1b KEYNOTE-B79 trial, which is evaluating the safety and clinical activity of CYAD-101 given concurrently with FOLFOX and followed by pembrolizumab in patients with unresectable metastatic colorectal cancer.

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022

Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.

BiTEs, CAR T-Cell Therapy, and ADCs Offer Variety of Lymphoma Treatment Options, But Questions Remain

July 22nd 2022

An influx of bispecific T-cell engagers, CAR T-cell therapies, and antibody-drug conjugates have revolutionized the treatment of hematologic malignancies; however, with several options in the sandbox, accessibility and unexplored clinical questions present challenges for optimal integration of these options into treatment.

Individualized Care Drives Treatment Focus in AML, DLBCL, and CLL

July 11th 2022

Ehab Atallah, MD, explains how patient characteristics influence current treatment strategies in acute myeloid leukemia, how frontline pirtobrutinib may move toward use in chronic lymphocytic leukemia, and the growing evidence favoring CAR T-cell therapy as an effective treatment option in CLL.

Anbalcabtagene Autoleucel Elicits Meaningful Responses in Relapsed/Refractory LBCL

July 8th 2022

The CAR T-cell therapy anbalcabtagene autoleucel generated strong overall response rates in patients with relapsed/refractory large B-cell lymphoma.

Tisa-cel Adds a Potential New ‘Standard-of-Care’ in Third-Line Treatment of Follicular Lymphoma

July 6th 2022

Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.

Brexucabtagene Autoleucel Has Durable Efficacy in B-ALL, Irrespective of Age and Tumor Burden

July 4th 2022

Bijal Shah, MD, MS, discusses the long-term data from the ZUMA-3 trial of brexucabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and spotlighted additional areas ripe for further exploration.

Axi-cel Gains European Approval for Relapsed/Refractory Follicular Lymphoma

June 28th 2022

The European Commission has granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after 3 or more prior lines of systemic therapy.

Cilta-cel Elicits an ORR of 100% in Multiple Myeloma After Early Relapse on Initial Therapy

June 24th 2022

The CAR T-cell therapy ciltacabtagene autoleucel generated a high response rate in patients with multiple myeloma who experienced early clinical relapse or failure to initial therapy.

FDA Grants Orphan Drug Designation to MB-106 for Waldenström Macroglobulinemia

June 22nd 2022

The FDA has granted an orphan drug designation to the CD20-targeted autologous CAR T-cell therapy, MB-106, for use as a potential therapeutic option in patients with Waldenström macroglobulinemia.

Cilta-cel Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

June 20th 2022

A single infusion of the CAR T-cell therapy ciltacabtagene autoleucel produced deep and durable responses in patients with relapsed/refractory multiple myeloma with a manageable toxicity profile, according to long-term follow-up data of the phase 1b/2 CARTITUDE-1 trial.

European Medicines Agency Validates Type II Variation Application for Liso-cel in Second-line LBCL

June 20th 2022

The European Medicines Agency has verified its type II variation application to extend the indication for lisocabtagene maraleucel to include the treatment of adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma, who are refractory or have relapsed within 12 months of initial therapy and are candidates for hematopoietic stem cell transplant.

FDA Panel Gives Beti-Cel Unanimous Support of Benefit in β-thalassemia

June 14th 2022

The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted unanimously in favor of the benefit of betibeglogene autotemcel for the treatment of transfusion-dependent β-thalassemia in adult and pediatric patients with a non–β0/β0 genotype.

FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

May 27th 2022

The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Quadruplets, Bispecific Antibodies, and CAR T-Cell Therapies Usher in Advances in Multiple Myeloma

May 27th 2022

Noopur Raje, MD, reviews the benefits of quadruplet regimens in the up-front and relapsed settings, treatment options for relapsed/refractory disease, and the possibilities for combinations to minimize toxicities in those who receive CAR T-cell or bispecific antibody therapies.

Dr. Raje on Unmet Needs with CAR T-Cell Therapy in Myeloma

May 25th 2022

Noopur Raje, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Dr. Deol on Collaboration in the Administration of CAR T-cell Therapy

May 20th 2022

Abhinav Deol, MD, discusses the importance of communication and collaboration in CAR T-cell therapy.

Trial Assessing CAR T-Cell Therapy ACLX-001 in Relapsed/Refractory Multiple Myeloma Begins

May 19th 2022

Investigators have initiated a phase 1 trial exploring ACLX-001, a novel CAR T-cell therapy using the ARC-SparX platform, in patients with relapsed/refractory multiple myeloma.